| Literature DB >> 28559930 |
Bettina Wöchtl1, Florian Gunzer2, Wilhelm Gerner3, Hagen Gasse4, Michaela Koch1, Zoltán Bagó5, Martin Ganter6, Herbert Weissenböck7, Nora Dinhopl7, Sina M Coldewey8,9, Alexandra von Altrock6, Karl-Heinz Waldmann6, Armin Saalmüller3, Kurt Zimmermann10, Jörg Steinmann11, Jan Kehrmann11, Ludger Klein-Hitpass12, Jochen Blom13, Ralf Ehricht14, Ines Engelmann14, Isabel Hennig-Pauka1.
Abstract
BACKGROUND: Shiga toxin (Stx) producing Escherichia coli (E. coli) (STEC) is the most frequent cause of diarrhoea-positive haemolytic uraemic syndrome (D + HUS) in humans. In 2011, a huge outbreak with an STEC O104:H4 strain in Germany highlighted the limited possibilities for causative treatment of this syndrome. The responsible STEC strain was found to combine Stx production with adherence mechanisms normally found in enteroaggregative E. coli (EAEC). Pathotypes of E. coli evolve and can exhibit different adhesion mechanisms. It has been shown previously that neonatal gnotobiotic piglets are susceptible for infection with STEC, such as STEC O157:H7 as well as for EAEC, which are considered to be the phylogenetic origin of E. coli O104:H4. This study was designed to characterise the host response to infection with the STEC O104:H4 outbreak strain in comparison to an STEC O157:H7 isolate by evaluating clinical parameters (scoring) and markers of organ dysfunction (biochemistry), as well as immunological (flow cytometry, assessment of cytokines/chemokines and acute phase proteins) and histological alterations (light- and electron microscopy) in a gnotobiotic piglet model of haemolytic uraemic syndrome.Entities:
Keywords: E. coli O104:H4; E. coli O157:H7; Enteroaggregative E. coli; Enterohaemmorrhagic E. coli; Gnotobiotic piglets; Haemolytic uraemic syndrome (HUS); Shiga toxin; Swine
Year: 2017 PMID: 28559930 PMCID: PMC5445466 DOI: 10.1186/s13099-017-0179-8
Source DB: PubMed Journal: Gut Pathog ISSN: 1757-4749 Impact factor: 4.181
Infective dose administered, bacteriological and clinical findings in individual animals
| Group animal number | Infective dose (CFUs) | CFUs/g stool day 4 p.i. | CFUs/g stool day 5–6 p.i. | OD Stx ELISA day 5–6 p.i. | CFUs/g stool day 9–12 p.i. | OD Stx ELISA day 9–12 p.i. | Average clinical score (animal/group) | Clinical signs, assessed at least once | Day of death |
|---|---|---|---|---|---|---|---|---|---|
| Negative | |||||||||
| 1 | Mock | Sterile | Sterile | n.a. | Sterile | 0.009 (N) | 0.00 | None | 10 |
| 2 | Mock | Sterile | Sterile | 0.025 (N) | Sterile | 0.012 (N) | 0.11 | Reduced appetite | 9 |
| 3 | Mock | Sterile | Sterile | 0.020 (N) | 0.00 | None | 6a | ||
| Ø 0.04 | |||||||||
|
| |||||||||
| 4 | 1.00 × 109 | 1.22 × 1010 | 2.81 × 1010 | n.a. | 8.60 × 108 | 4.538 (P) | 0.53 | Reduced appetite, dehydration | 10 |
| 5 | 1.00 × 109 | 8.17 × 109 | 6.88 × 1010 | n.a. | 2.62 × 109 | 3.993 (P) | 0.51 | Reduced appetite, dehydration, mild central nerval signs | 10 |
| 6 | 2.19 × 108 | 2.13 × 1010 | 3.38 × 107 | n.a. | Sterile | 2.746 (P) | 0.46 | Reduced appetite, dehydration | 10 |
| 7 | 2.19 × 108 | 1.18 × 107 | 2.10 × 109 | n.a. | Sterile | 3.492 (P) | 0.52 | Reduced appetite, mild central nerval signs | 9 |
| 8 | 2.19 × 108 | 3.13 × 109 | 1.63 × 109 | 4.122 (P) | 0.07 | Reduced appetite | 6a | ||
| 9 | 2.19 × 108 | 5.58 × 109 | 1.11 × 1010 | 2.833 (P) | 4.65 × 107 | 4.561 (P) | 0.11 | Reduced appetite, dehydration | 12 |
| Ø 0.37 | |||||||||
|
| |||||||||
| 10 | 2.20 × 108 | 5.43 × 109 | . | 0.74 | Severe neurological signs | 4b | |||
| 11 | 2.20 × 108 | 1.02 × 1010 | 8.35 × 109 | n.a. | 5.95 × 109 | 4.599 (P) | 0.67 | Mild central nerval signs, dehydration | 11 |
| 12 | 2.08 × 108 | 1.95 × 107 | 2.50 × 107 | 4.358 (P) | 0.30 | Severe neurological signs | 5b | ||
| 13 | 2.08 × 108 | 1.30 × 109 | 1.37 × 108 | 4.527 (P) | 0.50 | Dehydration | 5b | ||
| Ø 0.55 | |||||||||
Interpretation Shiga toxin ELISA: optical density (OD) < 0.070 = negative; OD > 0.070/<0.100 = indefinite, ODs > 0.100 = positive
n.a. not assessed, N negative, P positive
aEuthanized early due to organisational reasons
bEuthanized early due to severe clinical symptoms
Antibody panels used for immunophenotyping by flow cytometry
| Cell population addressed | Antigen | Clone | Isotype | Fluorochrome | Labelling strategy | Source of primary Ab |
|---|---|---|---|---|---|---|
| Myeloid cells, B cells and CD4+ T cells | CD3 | PPT3 | IgG1 | BV 421a | Biotin–streptavidin | In-house |
| CD79α | HM57 | IgG1 | PE | Direct conjugation | Dako | |
| CD172α | 74-22-15 | IgG1 | Alexa Fluor 647b | Direct conjugation | In-house | |
| CD4 | 74-12-4 | IgG2b | Alexa 488c | Secondary antibody | In-house | |
| T cells and NK-cell subpopulations | CD3 | PPT3 | IgG1 | BV 421a | Biotin–streptavidin | In-house |
| CD4 | 74-12-4 | IgG2b | Alexa Fluor 488c | Secondary antibody | In-house | |
| CD8α | 11/295/33 | IgG2a | PEd | Secondary antibody | In-house | |
| NKp46 | VIV-KM1 | IgG1 | Alexa Fluor 647b | Direct conjugation | In-house | |
| γδ T-cell subpopulations | TCR-γδ | PPT16 | IgG2b | BV421a | Biotin–streptavidin | In-house |
| CD8α | 11/295/33 | IgG2a | Alexa Fluor 647b | Direct conjugation | In-house | |
| CD27 | b30c7 | IgG1 | PEe | Secondary antibody | In-house | |
| CD2 | MSA4 | IgG2a | Alexa Fluor 488f | Direct conjugation | In-house |
aBrilliant Violet 421 streptavidin, BioLegend, San Diego, CA, USA
bAlexa Fluor 647 Protein Labelling Kit, Invitrogen, Carlsbad, CA, USA
cGoat anti-Mouse IgG2b-Alexa Fluor 488, Invitrogen, Carlsbad, CA, USA
dGoat anti-Mouse IgG2a-PE, Southern Biotech, Birmingham, AL, USA
eGoat anti-Mouse IgG1-PE, Southern Biotech, Birmingham, AL, USA
fAlexa Fluor 488 Protein Labelling Kit, Invitrogen, Carlsbad, CA, USA
Fig. 1Gating strategy in flow cytometry for identification of myeloid cells and lymphocyte subpopulations. Representative data from one animal is shown. a Lymphocytes (scattered line) or lymphocytes and myeloid cells together (solid line) were gated according to forward scatter/side scatter properties (FSC/SSC). Dead cells were excluded in a consecutive gate. Live cells were further analysed by three different panels of antibodies (b–d, see also Table 2), used to identify various immune cell subpopulations. b Gate 1 CD79α+ cells (B cells); gate 2 CD172 α+ cells (myeloid cells); gate 3 CD3+CD4+ cells (CD4 T cells). c Gate 1 CD3+ cells (total T cells); gate 2 CD3−CD8α+ cells (total NK cells); gate 3 (red rectangle): CD3−CD8α+NKp46− cells (NK-cell subpopulation); gate 4 (red rectangle): CD3−CD8α+NKp46+ cells (NK-cell subpopulation); gate 5 CD3+CD4−CD8 α+ (cytolytic T cells). d Gate 1 TCR-γδ+ cells (total γδ T cells); gate 2 (red rectangle): CD2+TCR-γδ+ cells (γδ T-cell subpopulation); gate 3 (red rectangle): CD2−TCR-γδ+ cells (γδ T-cell subpopulation); gate 4 CD2+CD8α+CD27+/−TCR-γδ+ cells (γδ T-cell subpopulation)
Standards, capture and detection antibodies used by FMIA
| Cytokine (bead region) | Standard | Capture Ab | Detection Ab |
|---|---|---|---|
| IL1β (26) | DY681, part 681-PIa | MAB6811a | BAF 681a |
| IL4 (34) | CSC1283, part 5S.128.10b | CSC1283, part 5S.128.09b | ASC0849b |
| IL8 (27) | RP0109S-005c | MCA1660d | MAB5351a |
| IL12 (36) | 912-PLa | MAB9121a | BAM9122a |
| CCL2 (53) | RP0017S-005c | Anti-poCCL2 clone 5-2e | Anti-poCCL2 clone 18-1e |
| IFNγ (43) | PPP022d | MP700b | MP701Bb |
| IL10 (28) | CSC0103, part SD064b | ASC0104b | ASC9109b |
aR&D Systems, Minneapolis, MN, USA
bThermo Fisher Scientific, Waltham, MA USA
cKingfisher Biotech, Biomol, Hamburg, Germany
dBio Rad, Hercules, CA, USA
eLunney lab, Beltsville, MD, USA
Laboratory diagnostic findings during the course of infection in blood
| Negative |
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median (min–max); number of animal examined | Median (min–max); number of animal examined | Median (min–max); number of animal examined | ||||||||
| Time range: reference range | T1 | T2 | T3 | T1 | T2 | T3 | T1 | T2 | T3 | |
| Red blood count | ||||||||||
| Haematocrit L/l | 0.21–0.37 | 0.29 (0.24–0.34); 3 | 0.24 (0.19–0.27); 3 | (0.24–0.29); 2 | 0.25 (0.19–0.35); 6 | 0.23 (0.21–0.29); 6 | 0.26 (0.18–0.33); 5 | 0.22 (0.14–0.31); 4 | 0.26 (0.23–0.33); 3 | 0.3; 1 |
| Haemoglobin g/l | 75.0–138.9 | 95.0 (78.0–112.0); 3 | 95.9 (79.3–124.0); 3 | (72.5–93.8); 2 | 81.5 (64.0–121.0); 6 | 87.3 (69.9–116.7); 6 | 83.2 (60.7–116.3); 5 | 72.5 (49.0–106.0); 4 | 78.8 (65.1–97.9); 3 | 96.8; 1 |
| Erythrocytes × 1012/l | 3.47–6.65 | 4.02 (3.41–5.10); 3 | 3.98 (2.69–4.43); 3 | (4.29–4.98); 2 | 3.64 (2.70–5.21); 6 | 3.79 (3.17–4.55); 6 | 4.67 (2.61–5.91); 5 | 3.17 (2.14–4.24); 4 | 4.86 (3.53–5.92); 3 | 5.32; 1 |
| Plateles × 109/l | 282–946 | 62 (21–107); 3 | 638 (543–910); 3 | (571–849); 2 | 80 (10–229); 6 | 549 (358–972); 6 | 925 (580–1180); 5 | 202 (31–266); 4 | 723 (215–998); 3 | 971; 1 |
| Normoblasts × 1012/l | 0.09 (0.08–0.13); 3 | 0.08 (0.06–0.11); 3 | (0.00–0.04); 2 | 0.06 (0.03–0.22); 6 | 0.05 (0.00–0.15); 6 | 0.22 (0.00–0.59); 5 | 0.09 (0.02–0.35); 4 | 0.33 (0.17–0.38); 3 | 0.93; 1 | |
| Blood chemistry | ||||||||||
| Creatinin µmol/l | 38–142 | 95 (84–99); 3 | 63 (57–67); 3 | (51–55); 2 | 86.5 (55–100); 6 | 57 (53–73); 6 | 68 (55–78); 5 | 103 (86–106); 3 | 63 (52–72); 4 | 87; 1 |
| GLDH U/l | 0–11.5 | 1.0 (0.5–2.0); 3 | (0.6–1.4); 2 | n.a. | 1.3 (0.6–2.1); 5 | 0.9 (0.1–2.1); 6 | 0.6 (0.5–2.0); 3 | 0.7 (0.3–0.9); 3 | 0.6 (0.2–1.0); 4 | 0.5; 1 |
| LDH U/l | 409–1549 | 2013 (1986–2830); 3 | 1105 (901–1445); 3 | (830–1061); 2 | 1893 (1150–2072); 6 | 1309 (909–1767); 6 | 806 (711–1255); 5 | 1301 (1185–1388); 3 | 710 (538–804); 4 | 824; 1 |
| CK U/l | 43–3343 | 598 (509–850); 3 | 98 (93–144); 3 | (85–195); 2 | 461 (292–1515); 6 | 194 (66–296); 6 | 91 (67–288); 5 | 303 (241–331); 3 | 87 (37–111); 4 | 96; 1 |
| ASAT U/l | 13.7–122.8 | 36 (36–55); 3 | 11 (11–22); 3 | (12–20); 2 | 25 (20–36); 5 | 20 (9–29); 6 | 14 (11–15); 5 | 19 (17–26); 3 | 9 (7–14); 4 | 11; 1 |
| Plasma protein g/l | 36.65–71.71 | 19.9 (19.5–22.9); 3 | 24.8 (23.9–27.8); 3 | (27.0–28.5); 2 | 23.9 (20.9–29.5); 5 | 28.8 (23.3–31.5); 6 | 31.2 (27.2–33.1); 5 | 22.7 (21.9–27.4); 3 | 30.1 (27.5–30.7); 4 | 31.4; 1 |
| Sodium mmol/l | 136.0–151.0 | 130.9 (129.0–132.5); 3 | 132.6 (130.6–133.4); 3 | (129.6–134.5); 2 | 130.8 (125.8–138.7); 6 | 133.7 (133.0–137.1); 6 | 131.7 (130.1–135.2); 5 | 132.0 (129.9–134.4); 3 | 132.3 (129.1–135.8); 4 | 129.5; 1 |
| Potassium mmol/l | 3.78–6.92 | 4.46 (3.32–4.75); 3 | 6.59 (5.74–7.60); 3 | (5.23–7.04); 2 | 4.66 (3.99–6.22); 6 | 5.75 (4.96–6.89); 6 | 5.79 (5.15–6.12); 5 | 4.65 (4.44–5.50); 3 | 5.26 (4.85–5.80); 4 | 4.97; 1 |
| Acute phase proteins | ||||||||||
| Haptoglobin mg/ml | (0.03–0.05); 2 | 0.02 (0.02–0.54); 3 | (0.01–0.02); 2 | 0.04 (0.04–0.06); 3 | 0.39 (0.04–0.91); 6 | 0.27 (0.02–1.13); 5 | (0.02–0.02); 2 | 2.62 (2.20–3.00); 4 | 1.27; 1 | |
| CRP mg/l | (<0.05–0.8); 3 | 3.0 (0.7–13.3); 3 | (1.2–3.4); 2 | 0.7 (<0.05–7.3); 5 | 7.5 (1.3–203.2); 6 | 11.0 (<0.05–40.9); 5 | (<0.05–1.7); 3 | 30.0 (9.5–220.1); 4 | 0.7; 1 | |
| LBP mg/l | 2.00 (1.00–6.50); 3 | 2.10 (1.20–4.00); 3 | (2.1–4.9); 2 | 2.80 (0.80–5.10); 5 | 4.25 (1.70–9.60); 6 | 4.7 (1.1–8.8); 5 | 1.20 (1.20–1.30); 3 | 5.05 (1.20–9.00); 4 | 7;1 | |
GLDH glutamate dehydrogenase, LDH lactate dehydrogenase, CK creatine kinase, ASAT aspartate transaminase, CRP C-reactive protein, LBP lipopolysaccharide binding protein, n.a. not assessed. T1 timerange 1, preinfectionem, T2 timerange 2, day 4-day 6 p.i., T3 timerange, day 7-day 12 p.i.
Results gained by urinalysis
| Group animal number | Erythrocytes/µl (Combur 9) | Bacteria in urine sediment | Erythrocytes in urine sediment | Squamous epithelial cells | Round epithelial cells | GFR | FE water % | FE Na % | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T2 | T3 | T2 | T3 | T2 | T3 | T2 | T3 | T2 | T3 | T2 | T3 | T2 | T3 | T2 | T3 | |
| Negative | ||||||||||||||||
| 1 | n | n.a. | n | n | n | (+) | (+) | ++ | (+) | ++ | 3.97 | 4.9 | 2.902 | 4.636 | 0.165 | 0.336 |
| 2 | 250 | n.a. | n | n.a. | + | n.a. | + | n.a. | + | n.a. | 4.39 | 4.55 | 3.851 | n.a. | 0.029 | n.a. |
| 3 | n | n.a. | n | n.a. | + | n.a. | n | n.a. | (+) | n.a. | 3.73 | n.a. | 4.682 | n.a. | 0.419 | n.a. |
|
| ||||||||||||||||
| 4 | n.a. | n | n.a. | +++ | n.a. | ++ | n.a. | + | n.a. | n | 4.63 | 3.68 | n.a. | 1.945 | n.a. | 0.23 |
| 5 | n.a. | n | n.a. | n.a. | n.a. | + | n.a. | n | n.a. | n | 4.24 | 3.21 | n.a. | 2.21 | n.a. | 0.299 |
| 6 | 250 | n.a. | +++ | +++ | n | n | ++ | (+) | + | n | 3.42 | 4.03 | 3.796 | 3.611 | 0.034 | 0.841 |
| 7 | n.a. | n | n.a. | ++ | n.a. | ++ | n.a. | n | n.a. | n | 4.55 | 4.55 | n.a. | 3.224 | n.a. | 0.21 |
| 8 | 250 | n.a. | + | n.a. | n | n.a. | n | n.a. | n | n.a. | 4.72 | n.a. | n.a. | n.a. | n.a. | n.a. |
| 9 | n | n.a. | +++ | n.a. | + | n.a. | + | n.a. | + | n.a. | 3.97 | 3.57 | 2.856 | n.a. | 1.061 | n.a. |
|
| ||||||||||||||||
| 10 | 50 | n.a. | ++ | n.a. | ++ | n.a. | n | n.a. | n | n.a | 4.1 | n.a. | 1.383 | n.a. | 0.015 | n.a. |
| 11 | n.a. | 250 | n.a. | +++ | n.a. | n | n.a. | n | n.a. | n | 4.81 | 2.87 | n.a. | 2.024 | n.a. | 0.341 |
| 12 | 0 | n.a. | ++ | n.a. | ++ | n.a. | n | n.a. | n | n.a. | 3.85 | n.a. | 2.565 | n.a. | 0.026 | n.a. |
| 13 | 250 | n.a. | n | n.a. | + | n.a. | n | n.a. | n | n.a. | 3.47 | n.a. | 2.035 | n.a. | 0.009 | n.a. |
n.a. not assessed, n negative, T1 timerange 1, preinfectionem, T2 timerange 2, day 4-day 6 p.i., T3 timerange, day 7-day 12 p.i.
Fig. 2Kidney of piglet infected with E. coli O157:H7. Arterial thrombosis (arrow) and severe glomerular hyalinisation (asterisk) are detectable
Fig. 3Electron microscopic images from E. coli O157:H7 and E. coli O104:H4 infected animals, respectively. a Colon ascendens of piglet infected with E. coli O157:H7. Bacteria are in intimate contact to epithelial cells, causing A/E lesions. Bar = 2500 nm. b Colon ascendens of piglet infected with E. coli O104:H4. Scattered bacteria in mucus above epithelial layer can be seen (arrowheads). No direct contact to epithelial cells is determinable. Bar = 2500 nm. c Colon ascendens of piglet infected with E. coli O157:H7. Bacteria are in intimate contact to epithelial cells, causing A/E lesions. Bar = 500 nm. d Glomerulum of the kidney of an E. coli O157:H7 infected piglet. Dilated subendothelial space caused by detachment of endothelial cells from basement membrane (arrow). Bar = 2500 nm
Fig. 4Brainstem of a piglet infected with E. coli O157:H7. Liquefaction necrosis: p proliferation of vessels, n neuronal necrosis, g gitter cells (lipid-laden microglia phagocytes)
Number of animals with histopathological alterations
| Negative; n = 3 |
|
| |
|---|---|---|---|
| CNS | |||
| Neuropil vacuolization | 3 | 5 | 4 |
| Submeningeal oedema | 0 | 0 | 1 |
| Perivascular oedema | 1 | 5 | 2 |
| Focal liquefaction necrosis in the brainstem | 0 | 0 | 1 |
| Acute white matter spongiosis in cerebellum/brainstem | 0 | 0 | 1 |
| Kidney | |||
| Thrombosis of renal arterioles | 0 | 3 | 2 |
|
| |||
| Submucosal oedema | 3 | 4 | 3 |
| Subserosal oedema | 1 | 4 | 2 |
| Crypt hypoplasia | 0 | 2 | 0 |
| Haematoidin/siderin/siderophages | 0 | 2 | 0 |
| Lymphoplasmocytic infiltration of the propria | 0 | 2 | 1 |
Fig. 5Frequencies and absolute numbers of various immune cell subsets in E. coli infected and control animals. Dots in scatter plots represent values of individual animals, red lines represent median value within group. Experimental groups are illustrated on the x-axes: 1 control group (n = 3), 2 E. coli O104:H4-infected group (n = 6), 3 E. coli O157:H7-infected group [n = 3 (PBMC), n = 4 (Ln)]. a Absolute number of leukocytes and leukocyte subpopulations obtained by differential counts in white blood cells from day 4 to 6 post infection. b–m Absolute number of lymphocyte subpopulations and myeloid cells in blood from day 4 to 6 post infection and percentage of lymphocyte subpopulations within live lymphocytes in lymph node (Ln) on the day of slaughter. b Total T cells (CD3+ phenotype). c Total B cells (CD79α+ phenotype). d Myeloid cells (CD172α+ phenotype). e Total NK cells (CD3−CD8α+ phenotype). f NKp46− NK cells (CD3−CD8α+NKp46− phenotype). g NKp46+ NK cells (CD3−CD8α+NKp46+ phenotype). h CD4+ T cells (CD3+CD4+ phenotype). i Cytolytic T cells (CD3+CD4−CD8α+ phenotype). [j Total γδ T cells (TCR-γδ+ phenotype]. j CD2+ γδ T cells (CD2+TCR-γδ+ phenotype). k CD2− γδ T cells (CD2−TCR-γδ+ phenotype). l CD2+CD8α+CD27+ γδ T cells (CD2+CD8α+CD27+TCR-γδ+ phenotype)
Systemic cytokines/chemokines measured in serum of piglets during course of infection using FMIA
| Negative |
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
| Median (min–max) | Median (min–max) | Median (min–max) | |||||||
| Time range: | T1, n = 3 | T2; n = 3 | T3; n = 2 | T1; n = 5 | T2; n = 6 | T3; n = 5 | T1; n = 3 | T2; n = 4 | T3; n = 1 |
| IL1β pg/ml | 6.3 (6.3–14.6) | 4.7 (3.3–6.5) | 5.6 (5.6–5.7) | 5.6 (5.0–8.1) | 5.6 (4.6–8.4) | 5.9 (3.9–7.0) | 7.7 (6.7–8.4) | 7.5 (5.5–8.9) | 8.8 |
| IL12 pg/ml | 279.7 (195.0–413.9) | 104.0 (101.4–126.9) | 2263.4 (106.5–4420.4) | 194.9 (152.8–10856.4) | 165.9 (91.3–714.8) | 91.3 (42.4–139.8) | 134.7 (126.9–243.1) | 197.1 (93.9–6247.2) | 352.5 |
| CCL2 pg/ml | 807.1 (730.7–3973.4) | 1529.7 (840.6–2935.0) | 2550.6 (1751.2–3350.0) | 536.4 (251.5–1176.4) | 1372.8 (570.1–3598.0) | 1917.8 (826.3–4011.7) | 603.1 (441.9–672.1) | 453.9 (365.4–513.5) | 677.3 |
| IFNγ pg/ml | 2.8 (0.0–13.6) | 0.0 (0.0–16.3) | 4.0 (0.0–8.0) | 0.0 (0.0–4.2) | 38.7 (2.8–582.8) | 5.5 (0.0–63.6) | 0.0 (0.0–4.2) | 48.3 (46.2–98.3) | 30.5 |
| IL10 pg/ml | 49.4 (45.0–51.5) | 11.2 (9.2–15.4) | 17.1 (16.7–17.5) | 29.5 (22.0–33.1) | 20.1 (18.8–30.0) | 11.5 (9.8–17.5) | 22.7 (22.5–26.2) | 19.4 (14.6–31.4) | 26.7 |
T1 timerange 1, preinfectionem, T2 timerange 2, day 4–day 6 p.i., T3 timerange, day 7–day 12 p.i.